Evidence review supports pediatric use of PDE 5 inhibitors for pulmonary hypertension
A systematic review of the comparative effectiveness and safety of phosphodiesterase type 5 (PDE-5) inhibitors in pediatric patients with pulmonary hypertension published Feb. 24, 2017 in Pediatrics demonstrates that scientific evidence supports the use of this class of medications in infants, neonates and children with pulmonary hypertension. In this review, these medicines were shown to improve echocardiography measurements, cardiac catheteriza…
Blocking Factor in Lungs Could Be Way to Treat Clotting Form of Pulmonary Hypertension
The discovery of a molecular factor that triggers blood clots in lung arteries may explain why chronic thromboembolic pulmonary hypertension (CTEPH) often occurs in patients without traditional clotting risk factors, according to a study.
SERAPHIN Trial: Study Finds Macitentan Can Improve Quality of Life for Some PH Patients
Patients with WHO Group 1 PH (PAH, pulmonary arterial hypertension), a serious, progressive and often fatal lung disease, typically have a number of symptoms and limitations that affect the quality of everyday living. Depending on the severity of the disease, patients may experience negative physical, social, emotional and psychological impacts. Research has indicated that >macitentan (Opsumit®), an endothelin receptor antagonist (ERA), might hel…
First Canadian Electrophysiology Laboratory Equipped with Robotic Magnetic Navigation System Dedicated to Patients with Congenital Heart Diseases
The Montreal Heart Institute is proud to announce the opening of the very first electrophysiology laboratory (EP Lab) equipped with robotic and magnetic navigation and dedicated to congenital heart diseases in Canada. Congenital heart diseases are cardiac malformations that affect approximately 1% of all Canadians. “The eimplementation of this cutting edge technology is a major advance. Thanks to this new lab, we will be able to perform intervent…
International Diagnosis and Management Practices for CTEPH Inadequate, Study Finds
An international study to assess clinical practices in the diagnosis and management of patients with chronic thromboembolic pulmonary hypertension (CTEPH) found several differences in CTEPH management among regions, but also a gap between guideline procedures and real-life practice of diagnosis and treatment.
CETPH Patients Suffer Depression, Anxiety, Poorer Quality of Life Than Those with PAH, Study Finds
A retrospective study found that patients with chronic thromboembolic pulmonary hypertension (CTEPH) have more pronounced decreases in mental health than those with pulmonary arterial hypertension (PAH). The German study, “Anxiety, Depression, and Health-Related QOL in Patients Diagnosed with PAH or CTEPH,” appeared in the journal Lung.
Merryman wins $6M to address heart disease with arthritis drug, fund other research
A Vanderbilt biomedical engineering professor has garnered $6 million total in grants to determine how to treat heart valve disease, pulmonary hypertension and heart failure using drugs originally developed for rheumatoid arthritis and applying the lessons learned from failed weight loss drugs.
Artificial intelligence creates 3D hearts to predict patient survival
Machine-learning has predicted death risk in people with serious heart disease faster and more accurately than current methods.
Interview with Judith Moatti: Natasha Hall Show
PAH patient Judith Moatti talks about PH and the importance of early diagnosis on the Natasha Hall show on CJAD 800AM Radio.
Will you soon be diagnosed just by breathing?
A 2,400-year-old medical hypothesis – that various diseases carry “chemical seals” identifiable in breath samples – has been confirmed by an international study led by Technion-Israel Institute of Technology Prof. Hossam Haick.
Recent News


Get the latest on PH treatments, community events and more when you subscribe to our newsletter